Neuropeptide W-23 (human) acts as an endogenous ligand for NPBW1 and NPBW2 receptors; increases L-type calcium current (ICa,L) in transfected human embryonic kidney 293 cells and vascular smooth muscle cells (VSMCs) via GPR7; enhances pan-phospho-PKC expression, intracellular diacylglycerol levels, and phospholipase C (PLC)-catalyzed second messenger production; elevates pressure-induced vasotone in rat mesenteric arteries; induces significant increases in mean arterial pressure (MAP) in conscious, freely moving male rats; stimulates total activity, ambulatory activity, and duration of stereotypy in rats; its pressor effect is abolished by phentolamine pretreatment; behavioral effects are significantly attenuated by pretreatment with the orexin type 1 receptor (OX1R) antagonist SB-408124; exhibits anorexigenic effects; and shows reduced expression in hypertensive rats.